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PSY57
WILLINGNESS TO PAY FOR OBESITY PHARMACOLOGY
Doyle S1, Lloyd A1, Birt J2, Curtis B2, Godbey K2, Ali S3
1Oxford Outcomes, Oxford, UK; 2Eli Lilly & Company, Indianapolis, IN, USA; 3University of 
York, York, UK
OBJECTIVES: Several different treatments for obesity have been licensed for use by 
FDA/EMA, but health insurers and other payers typically refuse to support access to 
them. Thus, patients are left to bear signiﬁ cant out of pocket costs for obesity treat-
ment. This study aims to assess preferences and willingness to pay (WTP) for obesity 
medications amongst patients seeking weight loss in the United States and United 
Kingdom. METHODS: An online WTP survey was developed based on a literature 
review, expert clinician interviews, and proﬁ les of available obesity therapies. Obese 
participants recorded their demographics, weight history, and indicated their prefer-
ence for hypothetical, paired-choice weight loss treatments which varied across 7 
attributes. RESULTS: A total of 502 participants (N = 251 US; N = 251 UK) completed 
the survey (73.5% female; 47.7 years of age). The mean Body Mass Index of the 
sample was 37.12 kg/m2 (±4.63). All treatment attributes were signiﬁ cantly important 
except “time to noticeable weight loss” (P < 0.001). Corrected for purchasing power 
parity, the combined country sample was willing to pay £6.40 per month per % of 
body weight reduction; £0.68 per % reduction in long-term health risk; £18.12 for a 
one-pill-per-day treatment vs. a daily injection (£14.79 for a three pill per day 
regimen); £7.34 for a treatment that required only small changes in lifestyle versus 
large changes in diet and exercise (£29.37 for one that required no changes). Partici-
pants were also willing to pay £15.05 per month for a treatment that avoided gastro-
intestinal upset or a 5 point increase in blood pressure. CONCLUSIONS: Participants 
placed a lot of value on weight loss and avoiding changes to their lifestyle (i.e. diet/
exercise), and much less value on reducing long terms risks to health. Avoiding side 
effects was also valued highly. 
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AVAILABILITY OF AND ACCESS TO ORPHAN DRUGS: AN 
INTERNATIONAL COMPARISON OF PHARMACEUTICAL TREATMENTS 
FOR PULMONARY ARTERIAL HYPERTENSION, FABRY DISEASE, 
HEREDITARY ANGIOEDEMA AND CHRONIC MYELOID LEUKEMIA
Blankart CR1, Stargardt T2, Schreyögg J3
1Helmholtz Zentrum München, Muenchen, Germany; 2Helmholtz Zentrum München, 
Neuherberg, Germany; 3Munich University, Munich, Germany
OBJECTIVES: To identify differences in the availability of orphan drugs and in patient 
access to them in eleven pharmaceutical markets: Australia, Canada, England, France, 
Germany, Hungary, the The Netherlands, Poland, Slovakia, Switzerland and the US. 
METHODS: Four rare diseases were selected for analysis: pulmonary arterial hyper-
tension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Indica-
tors for availability were deﬁ ned as the indications for which orphan drugs had been 
authorized in the treatment of these diseases, the application date and the date upon 
which these drugs received market authorization in each country. Indicators of patient 
access were deﬁ ned as the outcomes of technology appraisals, the extent of coverage 
provided by health care payers and the price of the drugs in each country. RESULTS: 
Most drugs included had received market authorization in all countries, but the range 
of indications for which they had been authorized differed by country. The broadest 
range of indications was found in Australia, and the largest variations in indications 
were found for PAH drugs. Authorization process speed, the time between application 
and market authorization, was fastest in the US with an average of 362 days followed 
by the EU (394 days). The highest prices for the included drugs were found in Germany 
and the US, and the lowest in Canada, Australia and England. Although the prices of 
all of the included drugs were high compared to those of most non-orphan drugs, 
most of the insurance plans in our country sample provided 100%coverage for autho-
rized drugs after a certain threshold. CONCLUSIONS: Although the present study 
showed some variations in selected indicators of availability and access to orphan 
drugs, virtually all of the drugs in question were available and accessible in our sample. 
Substantial copayments in the US and Canada, however, represent barriers to patient 
access, especially in the case of expensive treatments.
PSY59
ACCESSIBILITY AND UTILIZATION OF BORTEZOMIB IN DUTCH DAILY 
PRACTICE
Blommestein H, Franken M, Uyl-De Groot C
Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: The Dutch government introduced in 2002 policy regulations to 
provide additional ﬁ nancing for expensive inpatient pharmaceuticals. In 2006 the 
policy was revised after signals of ‘zipcode prescribing’ of trastuzumab (Herceptin®). 
The aim of this study is to examine national and regional utilization of the expensive 
drug bortezomib (Velcade®) and investigate whether accessibility issues exist in Dutch 
daily practice. In 2004 bortezomib received market approval and in 2006 it was added 
to the expensive drug list for the indication of multiple myeloma. METHODS: Our 
longitudinal study investigated sales data (excluding trial use) from 2004 to 2009 and 
compared these ﬁ gures with an estimation of the prevalence of patients with multiple 
myeloma. Prevalence was estimated from incidence ﬁ gures of the The Netherlands 
Comprehensive Cancer Centres. We calculated the percentage of patients treated with 
bortezomib at both national and regional level. In addition, interviews with hematolo-
gists were conducted investigating potential prescription barriers for bortezomib. 
RESULTS: At the national level, utilization gradually increased from treating 2% of 
the patients to 17%, indicating a long adjustment period. Furthermore, underutiliza-
tion might still be present since utilization is lower than 27%, which is the estimated 
percentage of eligible patients by the professional group. In 2009, regional utilization 
ranged from 12% to 24%. Even though interviews revealed that hematologists were 
aware of the high treatment costs, they did not experience absolute prescription bar-
riers. CONCLUSIONS: Utilization of bortezomib is increasing and accessibility has 
improved in the The Netherlands. However, the trend indicates a long adjustment 
period. Although hematologists did not experience absolute barriers, the indication of 
underutilization and residual regional differences might point towards accessibility 
issues in the The Netherlands, despite the policy revisions.
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RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW OF 
HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS): MORE 
RESEARCH IS NEEDED?
Guri S, Kumar J, Ghasolia D, Sharma Y, Saini P, Baghla G
JRDS ePharma Health Pvt Ltd, Dehli, India
OBJECTIVES: Results from a comprehensive literature review of hutchinson-gilford 
progeria syndrome (HGPS): more research is needed? METHODS: Information was 
retrieved from websites of World Health Organization, Pubmed, clinicaltrials.gov and 
relevant grey literature using key words like Progeria, HGPS etc. Data regarding 
prevalence rate and current treatment options were obtained and complied. RESULTS: 
Progeria is an extremely uncommon genetic condition (ICD-10.E34.8), wherein symp-
toms resembling aspects of aging are manifested at early age. To our knowledge, only 
four clinical trials are in-process and results are waiting. No randomized clinical trial 
has been reported till date. The prevalence rate of Progeria is approximately 1 per 4 
million births. a total of 150 cases have been reported since 1886 and 40 cases are 
living currently. The p.G608G LMNA mutation is the most commonly reported muta-
tion. Around 95% of patients are Caucasians and male to female ratio is anticipated 
as 1.5:1. Symptoms of the disease start appearing at an age of 6–12 months. The 
patients demonstrate a life expectancy of average 13 years (range: 7–27 years). Death 
largely occurs due to cardiovascular abnormalities. New treatment options include 
Farnesyltransferase inhibitor (FTI) (ABT-100) which is presently under clinical study 
conducted by Progeria Research Foundation (PRF). FTI has shown positive results in 
previous studies on animals. Clinical trials are in process evaluating Lonafarnib, 
Zoledronic Acid, and Pravastatin in retarding the process of aging in Progeria patients. 
Growth hormone treatment in a few patients has also shown growth in height by 10% 
and in weight by 50%. Improvement in joint stiffness and BMR has been observed 
with Physical therapy and occupational therapy. CONCLUSIONS: The pace of 
research in this area has increased in recent years. Extensive genetic research can play 
a vital role in the early treatment of this disease.
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RISK OF SURGICAL PROCEDURES IN THE INFLAMMATORY BOWEL 
DISEASE. ADMINISTRATIVE DATABASES AS A RESOURCE OF 
KNOWLEDGE
Lepore V1, D’Ettorre A1, Graziano G1, Scaccianoce G2, Vacca M1, Tognoni G1
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OBJECTIVES: To provide a comprehensive epidemiological proﬁ le of patients 
affected by Inﬂ ammatory Bowel Disease (IBD), and to assess the risk of preventable 
intestinal surgical procedures. METHODS: All cases of IBD identiﬁ ed in validated 
administrative databases of the Apulia region (about 4 millions inhabitants) in the 
period 1998–2006 were included in the study, and qualiﬁ ed by a record linkage 
process in terms of index clinical conditions and surgical procedures. Crohn’s disease 
(CD) and Ulcerative Colitis (UC), were considered separately in the analysis. Similarly, 
the surgical procedures coded according to the ICD9-CM were analyzed as a whole 
group, as well as separately for small and large intestine and rectum. Multivariate 
logistic regression was used to assess the risk to undergo surgery. Results were reported 
as Odds Ratios (OR) with 95% conﬁ dence intervals. RESULTS: We identiﬁ ed 11,991 
cases of IBD (4,279 and 7,712 for CD and UC, respectively). Intestinal surgery was 
more frequent in patients aged 18–64 years, in males and in subjects with CD. In the 
multivariate logistic regression the risk of any intestinal surgical procedure was higher 
for CD then UC patients (83%), in males vs. females (41%) and in 40–64 age class 
vs. older people (30%). Only in the case of UC, the youngest age class (0–17 years) 
had a major risk to undergo surgery of rectum (p-values 0.001). Furthermore, in the 
youngest age group (0–17 years) the difference between CD and UC risk to undergo 
any intestinal surgery was much less than adult age classes. No important differences 
were detected in the risk of at least one intestinal operation across the Apulia. 
CONCLUSIONS: The routine availability of a comprehensive, detailed, reliable 
system of record-linked databases allows to monitor timely risk of severe surgical 
procedures thus favoring the adoption of well targeted and updated health policy 
measures.
